[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2 A

Nuclear Medicine and Biology

Volumn 43, Issue 6, 2016, Pages 325-332

  Estrada, Sergio ^a   Lubberink, Mark ^a,b   Thibblin, Alf ^a,b   Sprycha, Margareta ^b   Buchanan, Tim ^c   Mestdagh, Nathalie ^c   Kenda, Benoit ^c   Mercier, Joel ^c   Provins, Laurent ^c   Gillard, Michel ^c   Tytgat, Dominique ^c,d   Antoni, Gunnar ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UCB PHARMA   (Belgium)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Epilepsy; Preclinical PET; SV2A; 11C UCB A

Indexed keywords

MEMBRANE PROTEIN; SYNAPTIC VESICLE PROTEIN 2 A; TRACER; UCB A C 11; UNCLASSIFIED DRUG; CARBON; ETIRACETAM; NERVE PROTEIN; PIRACETAM; SV2A PROTEIN, RAT;

ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLITE; NONHUMAN; PET-CT SCANNER; PIG; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN EXPRESSION; RADIATION DOSE; RADIOACTIVITY; RADIOCHEMISTRY; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; CHEMISTRY; DIAGNOSTIC IMAGING; METABOLISM; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; PIRACETAM; POSITRON-EMISSION TOMOGRAPHY; RATS; SWINE; TISSUE DISTRIBUTION;

EID: 84962782003     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2016.03.004     Document Type: Article

References (29)

1. Sander J.W., Shorvon S.D. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996, 61:433-443.
2. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
3. Robey R.W., Lazarowski A., Bates S.E. P-glycoprotein-a clinical target in drug-refractory epilepsy?. Mol Pharmacol 2008, 73:1343-1346.
4. Luna-Tortos C., Fedrowitz M., Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55:1364-1375.
5. Buckley K., Kelly R.B. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol 1985, 100:1284-1294.
6. Madeo M., Kovacs A.D., Pearce D.A. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae. J Biol Chem 2014, 289:33066-33071.
7. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2 A (SV2A). Proc Natl Acad Sci U S A 1999, 96:15268-15273.
8. Crevecoeur J., Kaminski R.M., Rogister B., Foerch P., Vandenplas C., Neveux M., et al. Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis. Neuropathol Appl Neurobiol 2014, 40:191-204.
9. Gillard M., Chatelain P., Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2 A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006, 536:102-108.
10. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004, 101:9861-9866.
11. Klitgaard H., Matagne A., Gobert J., Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998, 353:191-206.
12. Mercier J., Archen L., Bollu V., Carre S., Evrard Y., Jnoff E., et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2 A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem 2014, 9:693-698.
13. Bretin F., Bahri M.A., Bernard C., Warnock G., Aerts J., Mestdagh N., et al. Biodistribution and radiation dosimetry for the novel SV2A radiotracer [F]UCB-H: first-in-human study. Mol Imaging Biol 2015.
14. Bretin F., Warnock G., Bahri M.A., Aerts J., Mestdagh N., Buchanan T., et al. Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI Res 2013, 3:35.
15. Cai H., Mangner T.J., Muzik O., Wang M.W., Chugani D.C., Chugani H.T. Radiosynthesis of (11)C-levetiracetam: A potential marker for PET Imaging of SV2A expression. ACS Med Chem Lett 2014, 5:1152-1155.
16. Kenda B., Jnoff E. (UCB Pharma S.A., Brussels, Belgium) PCT Int. Pub. WO 2014/012563 2014.
17. Michel P., Differding E., Pasau P.M., Kenda B., Lallemand B., Matagne A., et al. (UCB Pharma S.A., Brussels, Belgium) PCT Int. Pub. WO 01/62726, WO 01/64637 2001.
18. Kenda B.M., Matagne A.C., Talaga P.E., Pasau P.M., Differding E., Lallemand B.I., et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 2004, 47:530-549.
19. Stabin M.G., Sparks R.B., Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46:1023-1027.
20. Watanabe M., Okada H., Shimizu K., Omura T., Yoshikawa E., Kosugi T., et al. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci 1997, 44:1277-1282.
21. Lubberink M., Kosugi T., Schneider H., Ohba H., Bergstrom M. Non-stationary convolution subtraction scatter correction with a dual-exponential scatter kernel for the Hamamatsu SHR-7700 animal PET scanner. Phys Med Biol 2004, 49:833-842.
22. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N- 11 C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990, 10:740-747.
23. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974, 19:716-723.
24. Lassen N.A., Bartenstein P.A., Lammertsma A.A., Prevett M.C., Turton D.R., Luthra S.K., et al. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 1995, 15:152-165.
25. van Vliet E.A., Aronica E., Redeker S., Boer K., Gorter J.A. Decreased expression of synaptic vesicle protein 2 A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 2009, 50:422-433.
26. Mohanraj R., Parker P.G., Stephen L.J., Brodie M.J. Levetiracetam in refractory epilepsy: a prospective observational study. Seizure 2005, 14:23-27.
27. Crevecoeur J., Foerch P., Doupagne M., Thielen C., Vandenplas C., Moonen G., et al. Expression of SV2 isoforms during rodent brain development. BMC Neurosci 2013, 14:87.
28. Klumpers U.M., Veltman D.J., Boellaard R., Comans E.F., Zuketto C., Yaqub M., et al. Comparison of plasma input and reference tissue models for analysing [(11)C]flumazenil studies. J Cereb Blood Flow Metab 2008, 28:579-587.
29. Finnema S.J., Nabulsi N., Mercier J., Lin S., Najafzadeh S., Ropchan J., et al. Evaluation of [11C]UCB-J as a novel PET radioligand for imaging synaptic vesicle glycoprotein 2 A (SV2A) in the human brain. 17th International Symposium on Cerebral Blood Flow, Metabolism and Function. Vancouver 2015, [Brain-0522].